Krystal Biotech Files Response With USPTO on KB801 Patent Application; Discontinues Clinical Study To Advance KB801 Into Pivotal Trial; No Safety Concerns Observed; No Further Subject-level Updates From Discontinued Study; Pivotal Trial Results Expected In Due Course